Retrieve available abstracts of 116 articles: HTML format
Single Articles
October 2025
LEOSDOTTIR M, Dahlbom L, Back M, Wallentin L, et al Data quality assessment in the SWEDEHEART registry: Insights from serial audits
on completeness and accuracy.
Am Heart J. 2025;288:149-158. PubMedAbstract available
September 2025
FEISTRITZER HJ, Jobs A, Zeymer U, Schneider S, et al Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI
and multivessel disease - Design and rationale of the randomized COMPLETE-NSTEMI
trial.
Am Heart J. 2025;287:94-106. PubMedAbstract available
August 2025
SARMA D, Smith R, Padkins M, Rali AS, et al Association between vasopressin administration and mortality in patients with
cardiogenic shock.
Am Heart J. 2025;286:88-96. PubMedAbstract available
DANDAMUDI K, Lawson BD, Barrett JC, Trankle CR, et al Trends of women in cardiovascular disease fellowships 2013-2022.
Am Heart J. 2025;286:111-115. PubMedAbstract available
July 2025
KHAN E, Lambrakis K, Briffa T, Cullen LA, et al Re-engineering the clinical approach to suspected cardiac chest pain assessment
in the emergency department by expediting research evidence to practice using
artificial intelligence. (RAPIDx AI)-a cluster randomized study design.
Am Heart J. 2025;285:106-118. PubMedAbstract available
DURAN AT, Barbecho JM, Shaw K, Ye S, et al Implementing depression treatment for cardiac populations in rapidly changing
contexts: Design of the hybrid effectiveness-implementation IHEART DEPCARE trial.
Am Heart J. 2025;285:52-65. PubMedAbstract available
June 2025
CUTLIP DE, Mehran R, Doros G, Kaplinskiy V, et al Prospective randomized single-blind multicenter study to assess the safety and
effectiveness of the SELUTION SLR 014 drug eluting balloon in the treatment of
subjects with in-stent restenosis: Rationale and design.
Am Heart J. 2025;284:11-19. PubMedAbstract available
May 2025
GENG Q, Ying Z, Zhenyan M, Renqiang Y, et al Long-term Prognostic Role of Persistent Microvascular Obstruction Determined by
Cardiac Magnetic Resonance for ST-segment Elevation Myocardial Infarction.
Am Heart J. 2025 May 29:S0002-8703(25)00187-5. doi: 10.1016/j.ahj.2025. PubMedAbstract available
MAINI AS, Abu-Much A, Redfors B, Wollmuth JR, et al Outcomes Among Patients with Coronary Bifurcation Lesions Undergoing
Impella-Supported High-Risk Percutaneous Coronary Intervention.
Am Heart J. 2025 May 22:S0002-8703(25)00176-0. doi: 10.1016/j.ahj.2025. PubMedAbstract available
WHITE HD, O'Brien SM, Boden WE, Fremes SE, et al Use of Coronary Artery Bypass Graft Surgery and Percutaneous Coronary
Intervention and Associated Outcomes in the ISCHEMIA Trial.
Am Heart J. 2025 May 20:S0002-8703(25)00165-6. doi: 10.1016/j.ahj.2025. PubMedAbstract available
GOLD ME, Kulkarni S, Yadalam A, Patel KJ, et al Cardiac Allograft Vasculopathy Mediates the Relationship Between Vitamin D
Deficiency and Cardiovascular Mortality Following Heart Transplantation.
Am Heart J. 2025 May 16:S0002-8703(25)00166-8. doi: 10.1016/j.ahj.2025. PubMedAbstract available
RAI B, Yildiz M, Bergstedt S, Bandari A, et al Diversity of Electrocardiographic Patterns in Left Main Culprit Acute
ST-Elevation Myocardial Infarction.
Am Heart J. 2025 May 14:S0002-8703(25)00164-4. doi: 10.1016/j.ahj.2025. PubMedAbstract available
MESSINGER MC, Ashburn NP, Chait JS, Snavely AC, et al Risk of delayed percutaneous coronary intervention for STEMI in the Southeast
United States.
Am Heart J. 2025 May 13:S0002-8703(25)00157-7. doi: 10.1016/j.ahj.2025. PubMedAbstract available
CARULLI E, McGarvey M, Chabok M, Panoulas V, et al Corrigendum to ;;Transcoronary cooling and dilution for cardioprotection during
revascularisation for ST-segment elevation myocardial infarction: design and
rationale of the STEMI-Cool study''. [Am Heart J. 2025:282:40-50].
Am Heart J. 2025;288:89. PubMed
JAMES S, Christoffersen AD, David JP, Hacker M, et al Effect of Once-Weekly Subcutaneous Semaglutide on Arterial Inflammation in People
with Type 2 Diabetes and Cardiovascular Disease Using PET-MRI: Primary Results of
a Randomized, Double-Blind, Placebo-Controlled Trial.
Am Heart J. 2025 May 7:S0002-8703(25)00156-5. doi: 10.1016/j.ahj.2025. PubMedAbstract available
KANDZARI DE, Latib A, Mylotte D, Ali ZA, et al Rationale and design of the prevail global trial program evaluating the prevail
drug-coated balloon in patients with in-stent restenosis and de novo small vessel
disease.
Am Heart J. 2025;283:26-36. PubMedAbstract available
April 2025
BERGER JS, Lyu C, Iturrate E, Westerhoff M, et al Opportunistic Assessment of Abdominal Aortic Calcification using Artificial
Intelligence (AI) Predicts Coronary Artery Disease and Cardiovascular Events.
Am Heart J. 2025 Apr 24:S0002-8703(25)00137-1. doi: 10.1016/j.ahj.2025. PubMedAbstract available
SOH CH, Chen J, Marwick TH Incidence Rate of Coronary Atherosclerosis among Cancer Types during
Survivorship: A Systematic Review and Meta-Analysis.
Am Heart J. 2025 Apr 23:S0002-8703(25)00142-5. doi: 10.1016/j.ahj.2025. PubMedAbstract available
CROOIJMANS C, Jansen T, van de Hoef TP, Paradies V, et al Design and rationale of the efficacy of endothelin receptor antagonism in
treatment of coronary artery spasm: a randomized controlled trial (EDIT-CAS).
Am Heart J. 2025 Apr 22:S0002-8703(25)00138-3. doi: 10.1016/j.ahj.2025. PubMedAbstract available
DILLINGER JG, Pezel T, Batias L, Angoulvant D, et al Twice-a-day administration of aspirin in patients with diabetes mellitus or
aspirin resistance after acute coronary syndrome: Rationale and design of the
randomized ANDAMAN trial.
Am Heart J. 2025 Apr 21:S0002-8703(25)00132-2. doi: 10.1016/j.ahj.2025. PubMedAbstract available
LI L, Sun H, Jin Z, Li J, et al Positive outcome trials driven by reduction in nonfatal myocardial infarction: A
systematic review and relevant guideline recommendations.
Am Heart J. 2025 Apr 18:S0002-8703(25)00136-X. doi: 10.1016/j.ahj.2025. PubMedAbstract available
HAKEEM A, Ali Shah J, Kumar R, Khan K, et al Rationale and Design of the TADCLOT Trial: A Double Blind Randomized Controlled
Trial Comparing Twice a Day Clopidogrel vs. Ticagrelor in Reducing Major Cardiac
Events in Patients with Acute STEMI Undergoing Primary Percutaneous Coronary
Intervention.
Am Heart J. 2025 Apr 12:S0002-8703(25)00103-6. doi: 10.1016/j.ahj.2025. PubMedAbstract available
NATHAN A Response to letter by Ferguson regarding article, "Revenues, costs, and
contribution margins of major inpatient cardiovascular procedures within the
Medicare population.".
Am Heart J. 2025 Apr 10:S0002-8703(25)00126-7. doi: 10.1016/j.ahj.2025. PubMed
FERGUSON M Letter by Ferguson regarding article, "Revenues, costs, and contribution margins
of major inpatient cardiovascular procedures within the Medicare population.".
Am Heart J. 2025 Apr 9:S0002-8703(25)00125-5. doi: 10.1016/j.ahj.2025. PubMed
SOMSEN YBO, de Winter RW, Wu J, Hoek R, et al Design and rationale of the drug-coated balloon coronary angioplasty versus
stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO)
trial.
Am Heart J. 2025 Apr 7:S0002-8703(25)00105-X. doi: 10.1016/j.ahj.2025. PubMedAbstract available
KULASINGAM A, Laustsen S, Busk M, Sand NP, et al Rationale and Design of VICAD-RISK study: Visualization of Coronary Artery
Disease for Modification of Risk Factors.
Am Heart J. 2025 Apr 3:S0002-8703(25)00107-3. doi: 10.1016/j.ahj.2025. PubMedAbstract available
PINCOMBE A, Gray J, Hickling S, Sanfilippo F, et al Cost-effectiveness of the transition from Conventional to High-Sensitivity
Troponin Assay for the Investigation and Management of Suspected Acute Coronary
Syndrome in the Emergency Department.
Am Heart J. 2025 Apr 2:S0002-8703(25)00104-8. doi: 10.1016/j.ahj.2025. PubMedAbstract available
CHO L, Nicholls SJ, Nordestgaard BG, Landmesser U, et al Design and rationale of Lp(a)HORIZON trial: Assessing the effect of
Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in
patients with CVD and elevated Lp(a).
Am Heart J. 2025 Apr 2:S0002-8703(25)00101-2. doi: 10.1016/j.ahj.2025. PubMedAbstract available
March 2025
HOFMANN R, James S, Sundqvist MO, Warme J, et al HELicobacter Pylori screening to prevent gastrointestinal bleeding in patients
with acute Myocardial Infarction(HELP-MI SWEDEHEART)Design and rationale of a
cluster randomized, crossover, registry-based clinical trial.
Am Heart J. 2025 Mar 27:S0002-8703(25)00096-1. doi: 10.1016/j.ahj.2025. PubMedAbstract available
NOORY N, Westin O, Borgersen EH, Kragelund C, et al Absence of Coronary Artery Disease in Patients Undergoing Coronary Imaging and
Association with Amyloidosis - A Danish Nationwide Study.
Am Heart J. 2025 Mar 26:S0002-8703(25)00093-6. doi: 10.1016/j.ahj.2025. PubMedAbstract available
ZEYMER U, Hassinger F, Bramlage P, Schafer A, et al Hyperoxemic Oxygen Therapy in Patients with Acute Anterior Myocardial Infarction:
HOT-AAMI - Design and Rationale of a Randomized Trial.
Am Heart J. 2025 Mar 21:S0002-8703(25)00095-X. doi: 10.1016/j.ahj.2025. PubMedAbstract available
OSUDE N, Spall HV, Bosworth H, Krychtiuk K, et al Advancement of the Implementation of Evidence-based Therapies for
Cardiovascular-Kidney-Metabolic Conditions: A Multi-Stakeholder Perspective.
Am Heart J. 2025 Mar 17:S0002-8703(25)00084-5. doi: 10.1016/j.ahj.2025. PubMedAbstract available
ONUMA Y, Ninomiya K, Sjauw K, Damman P, et al Accuracy of Instantaneous Wave-free Ratio and Fractional Flow Reserve Derived
From Single Coronary Angiographic Projections.
Am Heart J. 2025 Mar 11:S0002-8703(25)00071-7. doi: 10.1016/j.ahj.2025. PubMedAbstract available
BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al Olezarsen in Patients with Hypertriglyceridemia at High Cardiovascular Risk:
Rationale and Design of the Essence-TIMI 73b Trial.
Am Heart J. 2025 Mar 11:S0002-8703(25)00072-9. doi: 10.1016/j.ahj.2025. PubMedAbstract available
YU J, Indraratna P, Briggs NE, Brown P, et al Rationale and design of the TeleClinical Care (TCC) -Cardiac trial: A pragmatic
randomized trial of adjunctive virtual models of care in the secondary prevention
of cardiovascular events.
Am Heart J. 2025 Mar 11:S0002-8703(25)00091-2. doi: 10.1016/j.ahj.2025. PubMedAbstract available
SERPA F, Perera S, Cruz D, Figueroa JF, et al Cardiovascular Health, Lifestyle Factors, and Social Determinants Among Hispanic
or Latino Adults in the United States.
Am Heart J. 2025 Mar 9:S0002-8703(25)00070-5. doi: 10.1016/j.ahj.2025. PubMedAbstract available
LAI Y, Zhang S, Guo Y, Xu C, et al Apolipoprotein B modifies the association between lipoprotein(a) and ASCVD risk.
Am Heart J. 2025;281:157-167. PubMedAbstract available
PATEL S, Fung M, Prasai S, Butalia S, et al Emergency department visits and hospitalizations after a diagnosis of angina with
no obstructive coronary artery disease (ANOCA).
Am Heart J. 2025 Mar 1:S0002-8703(25)00067-5. doi: 10.1016/j.ahj.2025. PubMedAbstract available
February 2025
AUER J, Lamm G High-risk features and probability of ischemic and bleeding events after
percutaneous coronary intervention.
Am Heart J. 2025 Feb 26:S0002-8703(25)00058-4. doi: 10.1016/j.ahj.2025. PubMed
JACOBSEN MR, Jabbari R, Grove EL, Maeng M, et al Genotype-guided de-escalation and abbreviation of dual antiplatelet therapy in
patients with myocardial infarction and high bleeding risk: Design and rationale
of the investigator-initiated, multicenter, randomized, controlled trial,
DAN-DAPT.
Am Heart J. 2025 Feb 25:S0002-8703(25)00059-6. doi: 10.1016/j.ahj.2025. PubMedAbstract available
TAKAHASHI T, Wei J, Iribarren AC, Gulati M, et al Rationale and design of the Women's Ischemia Syndrome Evaluation Mechanisms of
Coronary Microvascular Dysfunction Leading to Pre-Heart Failure With Preserved
Ejection Fraction (WISE Pre-HFpEF).
Am Heart J. 2025 Feb 24:S0002-8703(25)00056-0. doi: 10.1016/j.ahj.2025. PubMedAbstract available
HAFF N, Horn DM, Bhatkhande G, Sung M, et al Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce
cardiovascular and renal risk in patients with type 2 diabetes: rationale and
design of a randomized controlled trial.
Am Heart J. 2025 Feb 20:S0002-8703(25)00038-9. doi: 10.1016/j.ahj.2025. PubMedAbstract available
GIBSON CM, Bahit MC, Mehran R, Mehta SR, et al Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome:
Rationale and Design of the Phase 3 (Librexia ACS).
Am Heart J. 2025 Feb 20:S0002-8703(25)00044-4. doi: 10.1016/j.ahj.2025. PubMedAbstract available
ERRIQUEZ A, Colaiori I, Hakeem A, Guiducci V, et al Functional Coronary Angiography to Indicate and Guide Revascularization in STEMI
Patients with Multivessel Disease: Rationale and Design of the AIR-STEMI trial:
Functional coronary angiography in STEMI patients.
Am Heart J. 2025 Feb 19:S0002-8703(25)00042-0. doi: 10.1016/j.ahj.2025. PubMedAbstract available
LEENING MJG, Khan CF, Zhu F, Singh SS, et al Lipoprotein(a) immunoassays and their associations with coronary artery
calcification and aortic valve calcification.
Am Heart J. 2025 Feb 18:S0002-8703(25)00040-7. doi: 10.1016/j.ahj.2025. PubMedAbstract available
TIAN Y, Wang X, Hu Z, Yu X, et al Design, rationale, and characterization of the Mobile health based OccuPational
cardiovascular risk intErventioN study (mHealth-OPEN Study).
Am Heart J. 2025 Feb 13:S0002-8703(25)00035-3. doi: 10.1016/j.ahj.2025. PubMedAbstract available
BAINEY KR, Welsh RC, Zheng Y, Arias-Mendoza A, et al Pharmaco-invasive Strategy and Dosing of Tenecteplase in STEMI Patients 60 to <75
Years: An Inter-trial Comparison of the STREAM-1 and STREAM-2 Trials: Comparison
of Patients 60 to <75 Years in STREAM-1 and -2.
Am Heart J. 2025 Feb 12:S0002-8703(25)00032-8. doi: 10.1016/j.ahj.2025. PubMedAbstract available
GAO XF, Kan J, Wu HY, Chen J, et al Intravascular Imaging-guided versus Angiography-guided Percutaneous Coronary
Intervention in Patients with Diabetes Mellitus: Rationale and design of an
International, Multicenter, Randomized IVI-DIABETES Trial.
Am Heart J. 2025 Feb 4:S0002-8703(25)00017-1. doi: 10.1016/j.ahj.2025. PubMedAbstract available
WANG G, Zhang R, Chen SL, Wang J, et al Targeted Therapy with a Localized abluminal Groove Low-Dose Sirolimus-Eluting
Bioabsorbable Polymer Coronary Stent in Chronic Total Occlusions: The TARGET CTO
Non-Inferiority Randomized Trial.
Am Heart J. 2025 Feb 3:S0002-8703(25)00018-3. doi: 10.1016/j.ahj.2025. PubMedAbstract available
MACHLINE-CARRION MJ, Girotto AN, Raupp P, Marton Pereira P, et al Rationale, design and pre-randomization data for a cluster randomized trial to
assess the effect of a digitally enabled quality improvement intervention on
LDL-C control in established atherosclerotic cardiovascular disease patients: The
SAPPHIRE-LDL
Am Heart J. 2025 Feb 3:S0002-8703(25)00020-1. doi: 10.1016/j.ahj.2025. PubMedAbstract available
January 2025
STEG PG, Nicolas J, Baber U, Sartori S, et al Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a
Large Randomized Clinical Trial: Insights From the TWILIGHT Trial.
Am Heart J. 2025 Jan 29:S0002-8703(25)00016-X. doi: 10.1016/j.ahj.2025. PubMedAbstract available
EFTEKHARI A, Christiansen EH, Lassen JF, Raungaard B, et al Randomized comparison of the combined Sirolimus eluting and endothelial
progenitor cell Combo(TM) stent vs. Biolimus eluting absorbable polymer coated
BioMatrix Alpha(TM) stent in patients undergoing percutaneous coronary
intervention. Rationale and s
Am Heart J. 2025 Jan 25:S0002-8703(25)00013-4. doi: 10.1016/j.ahj.2025. PubMedAbstract available
EBRAHIMI M, Fonarow GC Higher Levels of Glucose within the Normal Range and Cardiovascular Risk: A
Landscape Beyond Diabetes and Prediabetes.
Am Heart J. 2025 Jan 23:S0002-8703(25)00008-0. doi: 10.1016/j.ahj.2025. PubMed
PORTELA GT, Ducrocq G, Bertolet M, Alexander JH, et al Individualized transfusion decisions to minimize adverse cardiovascular outcomes
in patients with acute myocardial infarction and anemia.
Am Heart J. 2025 Jan 16:S0002-8703(25)00009-2. doi: 10.1016/j.ahj.2025. PubMedAbstract available
POLOMSKI EAS, Heemelaar JC, de Ronde MES, Al Jaff AAM, et al Increased Prevalence of Coronary Atherosclerosis in Cancer Survivors: A
Retrospective Matched Cross-sectional Study with Coronary CT Angiography.
Am Heart J. 2025 Jan 8:S0002-8703(25)00004-3. doi: 10.1016/j.ahj.2025. PubMedAbstract available
BRIX GS, Rasmussen LD, Rohde PD, Nissen L, et al Elevated lipoprotein(a) is independently associated with the presence of
significant coronary stenosis in de-novo patients with stable chest pain.
Am Heart J. 2025 Jan 7:S0002-8703(25)00001-8. doi: 10.1016/j.ahj.2025. PubMedAbstract available
VAN STEENWIJK MPJ, van Rosmalen J, Elzo Kraemer CV, Donker DW, et al A randomized embedded multifactorial adaptive platform for extra corporeal
membrane oxygenation (REMAP ECMO) - design and rationale of the left ventricular
unloading trial domain.
Am Heart J. 2025;279:81-93. PubMedAbstract available
December 2024
CARULLI E, McGarvey M, Chabok M, Panoulas V, et al Transcoronary cooling and dilution for cardioprotection during revascularisation
for ST-segment elevation myocardial infarction: design and rationale of the
STEMI-Cool study.
Am Heart J. 2024 Dec 30:S0002-8703(24)00338-7. doi: 10.1016/j.ahj.2024. PubMedAbstract available
BURGESS S, Zaman S, Towns C, Coylewright M, et al The under-representation of women in cardiovascular clinical trials:
State-of-the-art review and ethical considerations.
Am Heart J. 2024 Dec 27:S0002-8703(24)00340-5. doi: 10.1016/j.ahj.2024. PubMedAbstract available
NELSON AJ, Kaltenbach LA, McGuire DK, Levya M, et al Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and
atherosclerotic cardiovascular disease treated in US cardiology clinics.
Am Heart J. 2024 Dec 21:S0002-8703(24)00336-3. doi: 10.1016/j.ahj.2024. PubMedAbstract available
XU L, Xu H, Wu S, Zhang H, et al Indobufen-based Dual Antiplatelet Therapy in Patients with Multivessel Coronary
Disease Undergoing Drug-eluting Stent Implantation Insight From the OPTION Trial.
Am Heart J. 2024 Dec 20:S0002-8703(24)00335-1. doi: 10.1016/j.ahj.2024. PubMedAbstract available
CASSESE S, Simonetti F, Covarrubias HAA, Janisch M, et al Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary
Lithotripsy: Design and Rationale of ISAR-WAVE Trial.
Am Heart J. 2024 Dec 20:S0002-8703(24)00337-5. doi: 10.1016/j.ahj.2024. PubMedAbstract available
POLLACK LM, Chang A, Thompson MP, Keteyian SJ, et al Hospital-level variation in cardiac rehabilitation metrics.
Am Heart J. 2024 Dec 13:S0002-8703(24)00333-8. doi: 10.1016/j.ahj.2024. PubMedAbstract available
KAUL P, Barrett O, Savu A, Liyanage V, et al Association between adverse birth outcomes and long-term risk of premature
cardiovascular disease and mortality in a contemporary population-based cohort of
502,383 pregnant women.
Am Heart J. 2024 Dec 12:S0002-8703(24)00331-4. doi: 10.1016/j.ahj.2024. PubMedAbstract available
AARTS HM, Hemelrijk KI, Broeze GM, van Ginkel DJ, et al Deferral of routine percutaneous coronary intervention in patients undergoing
transcatheter aortic valve implantation: rationale and design of the PRO-TAVI
trial: the PRO-TAVI trial: rationale and design.
Am Heart J. 2024 Dec 12:S0002-8703(24)00332-6. doi: 10.1016/j.ahj.2024. PubMedAbstract available
IKEMURA N, Chan PS, Gosch K, Nguyen DD, et al Health Status Outcomes after Acute Myocardial Infarction in Patients without
Standard Modifiable Risk Factors.
Am Heart J. 2024 Dec 3:S0002-8703(24)00317-X. doi: 10.1016/j.ahj.2024. PubMedAbstract available
REDDY KP, Shutlz K, Eberly LA, Khatana SAM, et al Revenues, costs, and contribution margins of major inpatient cardiovascular
procedures within the Medicare population.
Am Heart J. 2024 Dec 2:S0002-8703(24)00305-3. doi: 10.1016/j.ahj.2024. PubMedAbstract available
BUDGEON CA, Nidorf S, Mosterd A, Fiolet A, et al Exploration of the regional effects of colchicine in the LoDoCo2 trial.
Am Heart J. 2024;278:186-194. PubMedAbstract available
KHAND A, Hatherley J, Dakshi A, Miller G, et al Safety and feasibility of triage and rapid discharge of patients with chest pain
from emergency room: A pragmatic, randomized noninferiority control trial of the
European Society of Cardiology (ESC) 0 to 1 hour pathway vs conventional 0 to 3
hour acce
Am Heart J. 2024;278:235-247. PubMedAbstract available
November 2024
ARAIZA-GARAYGORDOBIL D, Gopar-Nieto R, Sierra-Lara Martinez JD, S Ajit M, et al A randomized trial of antithrombotic therapy in patients with acute coronary
syndrome and coronary ectasia.
Am Heart J. 2024 Nov 28:S0002-8703(24)00304-1. doi: 10.1016/j.ahj.2024. PubMedAbstract available
FANAROFF AC, Vora AN, Wojdyla DM, Mehran R, et al Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days
alive and out of hospital: An analysis from AUGUSTUS.
Am Heart J. 2024 Nov 16:S0002-8703(24)00297-7. doi: 10.1016/j.ahj.2024. PubMedAbstract available
ENGEL-REBITZER E, Marinacci L, Zheng Z, Wadhera RK, et al Changes in coverage, access, and health status among adults with cardiovascular
disease after medicaid work requirements.
Am Heart J. 2024 Nov 14:S0002-8703(24)00276-X. doi: 10.1016/j.ahj.2024. PubMedAbstract available
NOORY N, Westin O, Maurer MS, Fosbol E, et al Chest pain and coronary artery disease in cardiac amyloidosis: Prevalence,
mechanisms, and clinical implications.
Am Heart J. 2024 Nov 14:S0002-8703(24)00296-5. doi: 10.1016/j.ahj.2024. PubMedAbstract available
ERLINGE D, Andersson J, Frobert O, Tornerud M, et al Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical
trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to
the zotarolimus-eluting Resolute Onyx stent.
Am Heart J. 2024;277:1-10. PubMedAbstract available
NAVAS-ACIEN A, Mark DB, Anstrom K, Lamas GA, et al Response to Tomoyuki Kawada: Blood and urine metal levels in patients with
diabetes and cardiovascular disease.
Am Heart J. 2024;277:143-144. PubMed
KAWADA T Blood and urine metal levels in patients with diabetes and cardiovascular
disease.
Am Heart J. 2024;277:142. PubMed
October 2024
BARONE-ROCHETTE G, Vanzetto G, Danchin N, Steg PG, et al Rationale and design of the multicentric randomized EVAOLD trial: evaluation of a
strategy guided by imaging versus routine invasive strategy in elderly patients
with ischemia.
Am Heart J. 2024 Oct 22:S0002-8703(24)00274-6. doi: 10.1016/j.ahj.2024. PubMedAbstract available
SHAH NP, Mulder H, Lydon B, Chiswell K, et al Real-World Exploration of LDL-Cholesterol Management in Patients with
Atherosclerotic Cardiovascular Disease.
Am Heart J. 2024 Oct 16:S0002-8703(24)00271-0. doi: 10.1016/j.ahj.2024. PubMedAbstract available
LUSK JB, Glover L, Soneji S, Granger CB, et al Cardiovascular event reduction among a US population eligible for semaglutide per
the SELECT trial.
Am Heart J. 2024;276:110-114. PubMedAbstract available
September 2024
VOLPP KG, Mahraj K, Norton LA, Asch DA, et al Design and Rationale of Penn Medicine Healthy Heart, a Randomized Trial of
Effectiveness of a Centrally Organized Approach to Blood Pressure and Cholesterol
Improvement Among Patients at Elevated Risk of Atherosclerotic Cardiovascular
Disease.
Am Heart J. 2024 Sep 26:S0002-8703(24)00262-X. doi: 10.1016/j.ahj.2024. PubMedAbstract available
KODAIRA M, Hasan MS, Grossman Y, Guerrero C, et al Risk of Cardiovascular Events after Influenza Infection-related Hospitalizations
in Adults with Congenital Heart Disease -A Nationwide Population Based Study.
Am Heart J. 2024 Sep 4:S0002-8703(24)00226-6. doi: 10.1016/j.ahj.2024. PubMedAbstract available
NELSON MD, Gomez-Arnold JM, Wei J, Lauzon M, et al Contributors to high left ventricular ejection fraction in women with ischemia
and no obstructive coronary artery disease: Results from the Women's Ischemia
Syndrome Evaluation - Coronary Vascular Dysfunction (WISE-CVD) Study.
Am Heart J. 2024 Sep 2:S0002-8703(24)00224-2. doi: 10.1016/j.ahj.2024. PubMedAbstract available
DE COCK E, Kautbally S, Timmermans F, Bogaerts K, et al Low-dose colchicine for the prevention of cardiovascular events after
percutaneous coronary intervention: rationale and design of the COL BE PCI trial:
Short title: Rationale and design of the COL BE PCI trial.
Am Heart J. 2024 Sep 2:S0002-8703(24)00225-4. doi: 10.1016/j.ahj.2024. PubMedAbstract available
August 2024
HAMID H, Bagheri M, Benzing T, Krishnan S, et al Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT:
Rationale and design of the Tirzepatide treatment on coronary atherosclerosis
progression: The (T-PLAQUE) randomized-controlled trial design: tirzepatide and
plaque.
Am Heart J. 2024 Aug 24:S0002-8703(24)00218-7. doi: 10.1016/j.ahj.2024. PubMedAbstract available
JIANG C, Wang Z, Du X, Wang Y, et al Protocol for a randomized controlled trial of intensive blood pressure control on
cardiovascular risk reduction in patients with atrial fibrillation: rationale and
design of the CRAFT trial.
Am Heart J. 2024 Aug 23:S0002-8703(24)00203-5. doi: 10.1016/j.ahj.2024. PubMedAbstract available
BROWN TM Cholesterol Lowering Therapy is Highly Efficacious in Reducing Atherosclerotic
Cardiovascular Disease Risk but Grossly Underutilized: How do we Move the Needle?
Am Heart J. 2024 Aug 16:S0002-8703(24)00201-1. doi: 10.1016/j.ahj.2024. PubMed
DISMORR M, Granbom-Koski M, Ellfors E, Ruck A, et al Sex differences and long-term clinical outcomes after transcatheter aortic valve
replacement: a SWEDEHEART study.
Am Heart J. 2024 Aug 9:S0002-8703(24)00185-6. doi: 10.1016/j.ahj.2024. PubMedAbstract available
AIHARA K, Torii S, Nakamura N, Hozumi H, et al Pathological Evaluation of Predictors for Delayed Endothelial Coverage After
Currently Available Drug-eluting Stent Implantation in Coronary Arteries: Impact
of Lesions With Acute and Chronic Coronary Syndromes.
Am Heart J. 2024 Aug 7:S0002-8703(24)00197-2. doi: 10.1016/j.ahj.2024. PubMedAbstract available
STAHLI BE, Linke A, Westermann D, Van Mieghem NM, et al A Randomized Comparison of the Treatment Sequence of Percutaneous Coronary
Intervention and Transcatheter Aortic Valve Implantation: Rationale and Design of
the TAVI PCI Trial.
Am Heart J. 2024 Aug 7:S0002-8703(24)00184-4. doi: 10.1016/j.ahj.2024. PubMedAbstract available
VOGEL B, Jou S, Sartori S, Farhan S, et al Impact of sex on outcomes associated with polyvascular disease in patients after
PCI.
Am Heart J. 2024 Aug 7:S0002-8703(24)00196-0. doi: 10.1016/j.ahj.2024. PubMedAbstract available
July 2024
ERBAY A, Penzel L, Abdelwahed YS, Heuberger A, et al Prognostic impact of quantitative flow ratio (QFR)-consistent complete
revascularization in patients with myocardial infarction and multivessel coronary
artery disease.
Am Heart J. 2024 Jul 19:S0002-8703(24)00177-7. doi: 10.1016/j.ahj.2024. PubMedAbstract available
SINGH K, Nikhare K, Gandral M, Aithal K, et al Rationale, Design and Baseline Characteristics of a Randomized Controlled Trial
of a Cardiovascular Quality Improvement Strategy in India: The C-QIP Trial.
Am Heart J. 2024 Jul 19:S0002-8703(24)00174-1. doi: 10.1016/j.ahj.2024. PubMedAbstract available
VERGHESE D, Hamal S, Ghanem A, Kinninger A, et al Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients
with STable CoROnary Artery Disease CoMpared to Placebo (EKSTROM) Trial -
Rationale and Design.
Am Heart J. 2024 Jul 17:S0002-8703(24)00171-6. doi: 10.1016/j.ahj.2024. PubMedAbstract available
June 2024
JEYAPRAKASH P, Pathan F, Ozawa K, Robledo KP, et al Restoring microvascular circulation with diagnostic ultrasound and contrast
agent: Rationale and Design of the REDUCE trial.
Am Heart J. 2024 Jun 27:S0002-8703(24)00162-5. doi: 10.1016/j.ahj.2024. PubMedAbstract available
WU ZM, Kan J, Ye F, You W, et al PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular
Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary
Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN
Study.
Am Heart J. 2024 Jun 26:S0002-8703(24)00157-1. doi: 10.1016/j.ahj.2024. PubMedAbstract available
D'ENTREMONT MA, Lee SF, Mian R, Kedev S, et al Design and Rationale of the CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial
Randomized Controlled Trial of Colchicine versus placebo and Spironolactone
versus placebo in Patients with Myocardial Infarction.
Am Heart J. 2024 Jun 25:S0002-8703(24)00161-3. doi: 10.1016/j.ahj.2024. PubMedAbstract available
RAMASESHAN R, Perera D, Reid A, Andiapen M, et al REGENERATE-COBRA: A Phase II randomized sham-controlled trial assessing the
safety and efficacy of intracoronary administration of autologous bone
marrow-derived cells in patients with refractory angina.
Am Heart J. 2024 Jun 9:S0002-8703(24)00146-7. doi: 10.1016/j.ahj.2024. PubMedAbstract available
SONG L, Guan C, Yu M, Sun Z, et al Sirolimus-eluting iron bioresorbable scaffold versus cobalt-chromium
everolimus-eluting stents in patients with coronary artery disease: rationale and
design of the IRONMAN-II trial.
Am Heart J. 2024 Jun 3:S0002-8703(24)00140-6. doi: 10.1016/j.ahj.2024. PubMedAbstract available
May 2024
MOK Y, Lu Y, Ballew SH, Sang Y, et al Premorbid physical activity and prognosis after incident myocardial infarction:
the Atherosclerosis Risk in Communities Study.
Am Heart J. 2024 May 7:S0002-8703(24)00120-0. doi: 10.1016/j.ahj.2024. PubMedAbstract available
KIM Y, Park H, Yoon HJ, Suh J, et al Fully Automated Quantitative Coronary Angiography Versus Optical Coherence
Tomography Guidance for Coronary Stent Implantation (FLASH): Study Protocol for a
Randomized Controlled Non-Inferiority Trial.
Am Heart J. 2024 May 7:S0002-8703(24)00119-4. doi: 10.1016/j.ahj.2024. PubMedAbstract available
ZHANG F, Tian M, Wang X, Zhang H, et al Rationale and design of a Single-center Randomized Trial to Compare the Graft
Patency between the Radial Artery and the No-touch Saphenous Vein in Coronary
Artery Bypass Grafting Surgery (GRAFT-CAB Study).
Am Heart J. 2024 May 4:S0002-8703(24)00117-0. doi: 10.1016/j.ahj.2024. PubMedAbstract available
NICHOLLS SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in
Participants With or at High Risk for Atherosclerotic Cardiovascular Disease:
Rationale and Designs of BROADWAY and BROOKLYN.
Am Heart J. 2024 May 3:S0002-8703(24)00116-9. doi: 10.1016/j.ahj.2024. PubMedAbstract available
COOPER JG, Ferguson J, Donaldson LA, Black KMM, et al Could paramedics use the HEART Pathway to identify patients at low-risk of
myocardial infarction in the prehospital setting?
Am Heart J. 2024;271:182-187. PubMedAbstract available
April 2024
SAPP JL, Tang ASL, Parkash R, Stevenson WG, et al A Randomized Clinical Trial of Catheter Ablation and Antiarrhythmic Drug Therapy
for Suppression of Ventricular Tachycardia in Ischemic Cardiomyopathy: The
VANISH2 Trial.
Am Heart J. 2024 Apr 20:S0002-8703(24)00096-6. doi: 10.1016/j.ahj.2024. PubMedAbstract available
KIM MC, Ahn JH, Hyun DY, Lim Y, et al Timing of fractional flow reserve-guided complete revascularization in patients
with ST-segment elevation myocardial infarction with multivessel disease:
Rationale and design of the OPTION-STEMI trial.
Am Heart J. 2024 Apr 17:S0002-8703(24)00078-4. doi: 10.1016/j.ahj.2024. PubMedAbstract available
DAUBERT MA, Stebbins A, Peragallo-Urrutia R, Chiswell K, et al Early Postpartum Blood Pressure Screening is Associated with Increased Detection
of Cardiovascular Risk Factors in Women with Hypertensive Disorders of Pregnancy.
Am Heart J. 2024 Apr 4:S0002-8703(24)00076-0. doi: 10.1016/j.ahj.2024. PubMedAbstract available
PARK DY, Jamil Y, Babapour G, Kim J, et al Association of Cardiovascular Diseases with Cognitive Performance in Older
Adults.
Am Heart J. 2024 Apr 2:S0002-8703(24)00077-2. doi: 10.1016/j.ahj.2024. PubMedAbstract available
March 2024
THOMAS A, Banna S, Shahu A, Ali T, et al Propofol vs etomidate for induction prior to invasive mechanical ventilation in
patients with acute myocardial infarction.
Am Heart J. 2024 Mar 28:S0002-8703(24)00074-7. doi: 10.1016/j.ahj.2024. PubMedAbstract available
WU Y, Hu L, Xie X, Li W, et al Different Dose Aspirin Plus Immunoglobulin (DAPI) for Prevention of Coronary
Artery Abnormalities in Kawasaki Disease: Study Protocol for a Multi-centre,
Prospective, Randomized, Open-label, Blinded End-point, Non-inferiority Trial.
Am Heart J. 2024 Mar 18:S0002-8703(24)00071-1. doi: 10.1016/j.ahj.2024. PubMedAbstract available
KRUCOFF M, Spirito A, Baber U, Sartori S, et al Ticagrelor With or Without Aspirin Following Percutaneous Coronary Intervention
in High-Risk Patients With Concomitant Peripheral Artery Disease: a subgroup
analysis of the TWILIGHT randomized clinical trial.
Am Heart J. 2024 Mar 6:S0002-8703(24)00053-X. doi: 10.1016/j.ahj.2024. PubMedAbstract available
February 2024
MEHDIPOOR G, Redfors B, Chen S, Gkargkoulas F, et al Hypertension, Microvascular Obstruction and Infarct Size in Patients with STEMI
Undergoing PCI: Pooled Analysis from 7 Cardiac Magnetic Resonance Imaging
Studies.
Am Heart J. 2024 Feb 29:S0002-8703(24)00050-4. doi: 10.1016/j.ahj.2024. PubMedAbstract available
ZIEGELSTEIN RC, Kronish IM, Thombs BD Depression Screening to Improve Clinical Outcomes in Coronary Heart Disease
Patients.
Am Heart J. 2024 Feb 22:S0002-8703(24)00044-9. doi: 10.1016/j.ahj.2024. PubMed
LEE SH, Lee SJ, Heo JH, Ahn SG, et al Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1
year after drug-eluting stent implantation: Design and rationale of the
randomized ADAPT AF-DES trial.
Am Heart J. 2024 Feb 22:S0002-8703(24)00041-3. doi: 10.1016/j.ahj.2024. PubMedAbstract available
DEHGHANI P, Singh J, Mancini GBJ, Stanberry L, et al Angiographic characteristics of Patients with STEMI and COVID-19 - Insights from
NACMI Registry.
Am Heart J. 2024 Feb 21:S0002-8703(24)00039-5. doi: 10.1016/j.ahj.2024. PubMedAbstract available
January 2024
ALVIAR CL, Li BK, Keller NM, Bohula-May E, et al Prognostic Performance of the IABP-SHOCK II Risk Score Among Cardiogenic Shock
Subtypes in the Critical Care Cardiology Trials Network Registry.
Am Heart J. 2024 Jan 6:S0002-8703(23)00361-7. doi: 10.1016/j.ahj.2023. PubMedAbstract available
November 2023
MUNHOZ D, Collet C, Mizukami T, Yong A, et al Rationale and design of the pullback pressure gradient (PPG) global registry.
Am Heart J. 2023;265:170-179. PubMedAbstract available